Journals / Türk Hijyen ve Deneysel Biyoloji Dergisi / 2010 / Cilt: 67 - Sayı: 1

PCNA expression in non-epithelial ovarian tumors and correlation of prognosis

Epitelyal olmayan over kanserlerinde PCNA ekspresyonu ve prognoza etkileri

Pages
13–19
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It was found that 83 % of patients were at postmenopausal period and 17 % premenopausal and in patient histories, 47 % of patients were smoking over the five years.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: In colorectal and bladder carcinoma PCNA is used as a proliferation marker.
📊
Key Findings & Data:METHODS: In 30 cases diagnosed with routine pathological procedures as non-epithelial ovarian cancer, the PCNA immunoreactivity was evaluated by a streptoavidin-biotin antibody complex.
💡
Conclusion & Impact:It was found that 83 % of patients were at postmenopausal period and 17 % premenopausal and in patient histories, 47 % of patients were smoking over the five years.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: In colorectal and bladder carcinoma PCNA is used as a proliferation marker. This study examined the utility of PCNA as a proliferation index in non-epithelial ovarian tumors. METHODS: In 30 cases diagnosed with routine pathological procedures as non-epithelial ovarian cancer, the PCNA immunoreactivity was evaluated by a streptoavidin-biotin antibody complex. The possible correlations between PCNA immunoreactivity and LI index with stage, grade and lymph node involvement in non epithelial ovarian tumors were investigated. RESULTS: In our study, mean patient age 52.6 ± 6.7 years old, mean parity 3.1±1.5 and mean BMI 26.7 ± 4.2 kg/m2 were determined. It was found that 83 % of patients were at postmenopausal period and 17 % premenopausal and in patient histories, 47 % of patients were smoking over the five years. Most common hystological type was found as Dysgerminoma (27%) and clinical stage distributions were determined as stage 1 (33%), stage 2 (13%), stage 3 (47%), stage 4 (7%) in all patients. Grade 1 (20%), Grade 2 (33%) and Grade 3 (47%) were found according to histological classification. In our study, it was determined in non-epithelial ovarian tumors that as stage and grade of tumor increased, PCNA immunoreactivity and LI index were also elevated statistically meaningful (p0.05). CONCLUSION: Further studies are needed in order to use PCNA as tumor proliferation index in non-epithelial ovarian tumors.

Özet

AMAÇ: PCNA kolorektal ve mesane karsinomlarında proliferasyon belirteci olarak kullanılmaktadır. Bu çalışmada, PCNA’nın non-epitelyal over tümörlerinde proliferasyon indeksi olarak kullanılabilirliği araştırılmıştır. YÖNTEMLER: Patolojik olarak non-epitelyal over kanseri tanısı alan 30 olgunun PCNA immünreaktivitesi, streptoavidin-biotin antikor kompleksi kullanılarak değerlendirilmiştir. PCNA immünreaktivitesi ve Lİ indeksi ile non-epitelyal tümörlerdeki stage, grade ve lenf nodu tutulumu arasındaki olası ilişki araştırılmıştır. BULGULAR: Çalışmamıza alınan hastaların yaş ortalaması 52.6 ± 6.7, ortalama doğum sayısı 3.1±1.5 ve ortalama vücut kitle indeksleri 26.7 ± 4.2 kg/m2 olarak belirlenmiştir. Olguların % 83’ü postmenopozal, % 17’si premenopozal dönemde olduğu, % 47’sinin 5 yıldan uzun süreli sigara kullanımı öyküsü bulunduğu saptanmıştır. En sık rastlanan histolojik tipin Disgerminom (% 27) olduğu, klinik evrelerine göre dağılımlarının ise; stage 1, 2, 3 ve 4 için sırasıyla % 33, % 13, % 47, % 7 olduğu gözlenmiştir. Histolojik olarak % 47’si grade 3, % 33’ü grade 2 ve % 20’si grade 1 olarak belirlenmiştir. Nonepitelial over tümörlerinde klinik stage ve grade arttıkça PCNA immunureaktivitesi ve Li indeksi de parelel olarak anlamlı artış göstermiştir (p0.05). SONUÇ: Non epitelial over tümörlerde klinik ve histolojik evre ile PCNA ekspresyonu arasında bir korelasyon bulunmakla beraber, tümör proliferasyonu indeksi olarak PCNA kullanımı için daha ileri çalışmalar yapılması gerekmektedir.

🔖

Cite This Article

DÜNDER, İ., ABİKE, F., ZENGEROĞLU, S. (2022). PCNA expression in non-epithelial ovarian tumors and correlation of prognosis. Türk Hijyen ve Deneysel Biyoloji Dergisi, Cilt: 67 - Sayı: 1, 13–19. https://ajindex.com/articles/625192

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Dodd JK, Henry RJW, Tyler PP, Houghton CRS. Cervical Carcinoma: A comparison of four potential biochemical tumor markers. Gynecol Oncol 1989; 32:248. Sciarra JJ, Knapp RC, Berhomitz RS. Naturel history and detection of ovarian cancer. Gynecol Obstet, 1984; 28: 1-14.
  2. Yavuz H, Tezcan S, Erk A. Over karsinomları. Kadın Genital Kanserleri Kitabı, 1978; 9: 385-438. Scully RE. Tumors of the ovary and mal developed gonads. Washington DC: Armed Forces Institute of Pathology, 1979; 16: 247-56.
  3. Abu-rustum NR, Aghajanian C. Management of malignant germ cell tumors of the ovary. Semin Oncol, 1998; 25(2): 235-42.
  4. Chen LM, Berek JS. Ovarian and Fallopian Tubes, In: Haskell CM, eds. Cancer Treatment. 5 th ed. Phidelphia. WB Saunders, 2000: 928-76.
  5. Imai A, Furvi T, Tamai T. Gynecologic tumors and symptoms in childhood and adolescence: 10 year experience. Gynecol Obstet, 1994; 45: 227-34.
  6. Obata NH, Nakasima N, Kawai M, Nikkanua F, Mombe s, Tomeda Y. Gonadoblastoma with disgerminoma in one ovary and gonadoblastoma with disgerminoma and yolc salk tumor in the contralateral ovary in a girl with 46XY karyotype. Gynecol Oncol, 1995; 58: 124-8.
  7. Arroyo JG, Harris W, Laden SA. Recurrent mixed germ cell sex cord stromal tumor of the ovary in an adult. Int J Gynecol Pathol, 1998; 17(3): 281-3.
  8. Miyachi K, Fritzler MJ, Tan EN. Autoantibody to nuclear antigen in proliferatif markers. J Immunology, 1978; 121: 2228-34.
  9. Ogata K, Kurki P, Celic J. Monoclonal antibodies to a nuclear protein associated DNA replication. Exp Cell Res, 1986; 168: 476-86.
  10. Iachino C, Katsikoyiannis N, Dallera F. Assessment of proliferating cell nuclear antigen (PCNA) immunoreactivity in carcinomas. Patholocia, 1995; 87: 56-8.
  11. Jaskulski D, Gatti C, Travali S, Calabretta B, Baserga R. Regulation of the proliferating cell nuclear antigen cyclin and thymidine kinase m RNA levels by growth factors. J Biol Chem, 1998; 263: 101-7.
  12. Scott RJ, Hall PA, Haldane JS et al. A comparison of immunohistochemical markers of cell proliferating with experimentally determined growth fraction. J Pathol, 1999; 165: 173. Andre F, Fiazzi K, Culline S, Droz JP, Gatineau M, Takahashi Y, Oudard S, Theadore C. Peritoneal carsinomatosis in germ cell tumor: relations with retroperitoneal lymph node dissection. Am J Clin Oncol, 2000; 23(5): 460-2.
  13. Benedet JL, Bender H, Ngan HY, Pecorelli S. FIGO staging classifcations and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology, 2000; 70(2):